Discussion about this post

User's avatar
Kanji Nakatsu's avatar

HI Maria: Another great column on lipid nanoparticles; keep them coming. You do a great job of describing how much we don't know about them and their cargoes. Basically we know about 0.0001% of what is needed to use these therapeutically. If the regulators understood this, they wouldn't be so cavalier about our public health.

You raise good questions in so many aspects of this technology. Unfortunately, more products are being approved. And more people will suffer adverse effects.

DANIEL SANTIAGO RPh, PharmD's avatar

Agreed. The exosome/EV recycling pathway collapses the LNP-versus-spike dichotomy. The Onpattro ~70% figure is the quantitative anchor that makes this hard to dismiss.

The pathway turns a single injection into a recursive dispersion process: primary transfected cells continuously repackage and re-export cargo (residual lipid, mRNA, and antigen) to secondary and tertiary tissues. This multi-tiered redistribution expands localized transfection into a systemic footprint that far outlasts standard pharmacokinetic predictions, effectively a fractal cascade of antigen and lipid exposure.

35 more comments...

Ready for more?